Aspirin-Exacerbated Respiratory Disease. Clinical Disease and Diagnosis.

Immunology and Allergy Clinics of North America

Volumn 33, Issue 2, 2013, Pages 147-161

  Bochenek, Grazyna ^a   Nizankowska Mogilnicka, Ewa ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Aspirin; Aspirin challenge; Aspirin hypersensitivity; Aspirin exacerbated respiratory disease; Nonsteroidal anti inflammatory drugs; Provocation test

Indexed keywords

ACETYLSALICYLIC ACID; BENOXAPROFEN; CELECOXIB; CORTICOSTEROID; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DICLOFENAC POTASSIUM; DIFLUNISAL; ETODOLAC; ETORICOXIB; FENOPROFEN CALCIUM; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; KETOPROFEN; KETOROLAC; LUMIRACOXIB; LYSINE ACETYLSALICYLATE; MECLOFENAMATE SODIUM; MEFENAMIC ACID; MELOXICAM; NABUMETONE; NAPROXEN; NIMESIL; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PARECOXIB; ROFECOXIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALDECOXIB;

ASPIRIN EXACERBATED RESPIRATORY DISEASE; ASTHMA; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CROSS REACTION; DIAGNOSTIC ACCURACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INHALATION TEST; LOW DRUG DOSE; MEDICAL HISTORY; NOSE PROVOCATION TEST; PREDICTIVE VALUE; PREVALENCE; PRICK TEST; PRIORITY JOURNAL; PROVOCATION TEST; RESPIRATORY TRACT DISEASE; REVIEW; SENSITIVITY AND SPECIFICITY; THORAX RADIOGRAPHY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; DRUG HYPERSENSITIVITY; HUMANS; PREVALENCE; RESPIRATORY TRACT DISEASES;

EID: 84877039941     PISSN: 08898561     EISSN: 15578607     Source Type: Journal    
DOI: 10.1016/j.iac.2012.10.002     Document Type: Review

References (59)

1. Kowalski M., Makowska J.S., Blanca M., et al. Hypersensitivity to nonsteroidal antiinflammatory drugs (NSAIDs) - classification, diagnosis and management: review of the EAACI/ENDA and GA2LEN/HANNA. Allergy 2011, 66:818-829.
2. Widal M.F., Abrami P., Lermoeyez J. Anaphylaxie et idiosyncrasie. Presse Med 1922, 30:189-192.
3. Samter M., Beers R.F. Concerning the nature of the intolerance to aspirin. J Allergy 1967, 40:281-293.
4. Samter M., Beers R. Intolerance to aspirin: clinical studies and consideration of its pathogenesis. Ann Intern Med 1968, 68:975-983.
5. Lee R.U., Stevenson D.D. Aspirin-exacerbated respiratory disease: evaluation and management. Allergy Asthma Immunol Res 2011, 3:3-10.
6. Kasper L., Sładek K., Duplaga M., et al. Prevalence of asthma with aspirin hypersensitivity in the adult population in Poland. Allergy 2003, 58:1064-1066.
7. Hedman J., Kaprio J., Poussa T., et al. Prevalence of asthma, aspirin intolerance, nasal polyps and chronic obstructive pulmonary disease in a population-based study. Int J Epidemiol 1999, 28:717-722.
8. Gomes E., Cardoso M.F., Praca F., et al. Self-reported drug allergy in a general adult Portuguese population. Clin Exp Allergy 2004, 34:1597-1601.
9. Vally H., Taylor M., Thompson P.J. The prevalence of aspirin intolerant asthma in Australian asthmatic patients. Thorax 2002, 57:569-574.
10. Jenkins C., Costello J., Hodge L. Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. BMJ 2004, 328:434-440.
11. Delaney J.C. The diagnosis of aspirin idiosyncrasy by analgesic challenge. Clin Allergy 1976, 6:177-181.
12. Weber R.W., Hoffman M., Raine D.A., et al. Incidence of bronchoconstriction due to aspirin, azo dyes, non-azo dyes, and preservatives in a population of perennial asthmatics. J Allergy Clin Immunol 1979, 64:32-37.
13. Szczeklik A., Nizankowska E., Duplaga M., AIANE Investigators Natural history of aspirin-induced asthma. Eur Respir J 2000, 16:432-436.
14. Berges-Gimeno M.P., Simon R.A., Stevenson D.D. The natural history and clinical characteristics of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2002, 89:474-478.
15. Stevenson D.D., Szczeklik A. Clinical and pathologic perspectives on aspirin sensitivity and asthma. J Allergy Clin Immunol 2006, 118:773-786.
16. Mascia K., Haselkorn T., Deniz Y.M., TENOR Study Group, et al. Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to treat asthma. J Allergy Clin Immunol 2005, 116:970-975.
17. The ENFUMOSA Study Group The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. Eur Respir J 2003, 22:470-477.
18. Kowalski M.L., CieŚlak M., Perez-Novo C.A., et al. Clinical and immunological determinants of severe/refractory asthma (SRA): association with Staphylococcal superantigen-specific IgE antibodies. Allergy 2011, 66:32-38.
19. Yoshimine F., Hasegawa T., Suzuki E., et al. Contribution of aspirin-intolerant asthma to near fatal asthma based on a questionnaire survey in Niigata Prefecture, Japan. Respirology 2005, 10:477-484.
20. Mascia K., Borish L., Patrie J., et al. Chronic hyperplastic eosinophilic sinusitis as a predictor of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2005, 94:652-657.
21. Lumry W.R., Curd J.G., Zeiger R.S., et al. Aspirin-sensitive rhinosinusitis: the clinical syndrome and effects of aspirin administration. J Allergy Clin Immunol 1983, 7:580-587.
22. Świerczyńska M., Nizankowska-Mogilnicka E., Zarychta J., et al. Nasal versus bronchial and nasal response to oral aspirin challenge: clinical and biochemical differences between patients with aspirin-induced asthma/rhinitis. J Allergy Clin Immunol 2003, 112:995-1001.
23. Szczeklik A., Nizankowska-Mogilnicka E., Sanak M. Hypersensitivity to aspirin and non-steroidal antiinflammatory drugs. Middleton's allergy: principles and practice 2009, Vol. 2:1227-1243. Mosby Elsevier, New York. 7th edition.
24. Bochenek G., Nizankowska E., Szczeklik A. Atopy trait in hypersensitivity to nonsteroidal anti-inflammatory drugs. Allergy 1996, 51:16-23.
25. Szczeklik A., Gryglewski R., Czerniawska-Mysik G. Relationship inhibition of prostaglandin biosynthesis by analgesics to asthma attacks in aspirin-sensitive patients. Br Med J 1975, 1:67-69.
26. Szczeklik A., Gryglewski R., Czerniawska-Mysik G. Clinical patterns of hypersensitivity to nonsteroidal anti-inflammatory drugs and their pathogenesis. J Allergy Clin Immunol 1977, 60:276-284.
27. Settipane R.A., Schrank P.J., Simon R.A., et al. Prevalence of cross reactivity with acetaminophen in aspirin-sensitive asthmatic subjects. J Allergy Clin Immunol 1995, 96:480-485.
28. Quarantino D., Romano A., Di Fonso M., et al. Tolerability of meloxicam in patients with histories of adverse reactions to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 2000, 84:613-617.
29. Bavbek S., Dursun A.B., Dursun E., et al. Safety of meloxicam in aspirin-hypersensitive patients with asthma and/or nasal polyps. A challenge-proven study. Int Arch Allergy Immunol 2007, 142:64-69.
30. Bavbek S., Celik G., Ediger D., et al. The use of nimesulide in patients with acetylsalicylic acid and nonsteroidal anti-inflammatory drug intolerance. J Asthma 1999, 36:657-663.
31. Bavbek S., Celik G., Ozer F., et al. Safety of selective COX-2 inhibitors in aspirin/nonsteroidal anti-inflammatory drug-intolerant patients: comparison of nimesulide, meloxicam, and rofecoxib. J Asthma 2004, 41:67-75.
32. Szczeklik A., Nizankowska E., Bochenek G., et al. Safety of a specific COX-2 inhibitor in aspirin-induced asthma. Clin Exp Allergy 2001, 31:219-225.
33. Stevenson D.D., Simon R.A. Lack of cross-reactivity between rofecoxib and aspirin-sensitive patients with asthma. J Allergy Clin Immunol 2001, 108:47-51.
34. Martin-Garcia C., Hinojosa M., Berges P., et al. Safety of a cyclooxygenase-2 inhibitor in patients with aspirin-sensitive asthma. Chest 2002, 121:1812-1817.
35. Woessner K.M., Simon R.A., Stevenson D.D. Safety of high-dose rofecoxib in patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2004, 93:339-344.
36. Woessner K.M., Simon R.A., Stevenson D.D. The safety of celecoxib in patients with aspirin-sensitive asthma. Arthritis Rheum 2002, 46:2201-2206.
37. Gyllfors P., Bochenek G., Overholt J., et al. Biochemical and clinical evidence that aspirin-intolerant asthma subjects tolerate the cyclooxygenase 2-selective analgetic drug celecoxib. J Allergy Clin Immunol 2003, 111:1116-1121.
38. Martin-Garcia C., Hinojosa M., Berges P., et al. Celecoxib, a highly selective COX-2 inhibitor, is safe in aspirin-induced asthma patients. J Investig Allergol Clin Immunol 2003, 13:20-25.
39. El Miedany Y., Youssef S., Ahmed I., et al. Safety of etoricoxib, a specific cyclooxygenase-2 inhibitor, in asthmatic patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2006, 97:105-109.
40. Valero A., Sanchez-Lopez J., Bartra J., et al. Safety of parecoxib in asthmatic patients with aspirin-exacerbated respiratory disease. Int Arch Allergy Immunol 2011, 156:221-223.
41. Baldassare S., Schandene L., Choufani G., et al. Asthma attacks induced by low doses of celecoxib, aspirin, and acetaminophen. J Allergy Clin Immunol 2006, 117:215-216.
42. Passero M. Cyclo-oxygenase-2 inhibitors in aspirin sensitive asthma. Chest 2003, 123:2155-2156.
43. Levy M.B., Fink J.N. Anaphylaxis to celecoxib. Ann Allergy Asthma Immunol 2001, 87:72-73.
44. Stevenson D.D. Anaphylactic and anaphylactoid reactions to aspirin and nonsteroidal anti-inflammatory drugs. Immunol Allergy Clin North Am 2001, 21:745-768.
45. Pleskow W.W., Stevenson D.D., Mathison D.A., et al. Aspirin-sensitive rhinosinusitis/asthma: spectrum of adverse reactions to aspirin. J Allergy Clin Immunol 1983, 71:574-579.
46. Dursun A.B., Woessner K.A., Simon R.A., et al. Predicting outcomes of oral aspirin challenges in patients with asthma, nasal polyps, and chronic sinusitis. Ann Allergy Asthma Immunol 2008, 100:420-425.
47. 4 glucuronide concentration in patients with aspirin-intolerant asthma after intravenous aspirin challenge. Clin Exp Allergy 2004, 34:1262-1269.
48. Nizankowska E., Bestyńska-Krypel A., ćmiel A., et al. Oral and bronchial provocation tests with aspirin for diagnosis of aspirin-induced asthma. Eur Respir J 2000, 15:863-869.
49. Dahlen B., Zetterstrom O. Comparison of bronchial and per oral provocation with aspirin in aspirin-sensitive asthmatics. Eur Respir J 1990, 3:527-534.
50. Milewski M., Mastalerz L., Nizankowska E., et al. Nasal provocation test with lysine-aspirin for diagnosis of aspirin-sensitive asthma. J Allergy Clin Immunol 1998, 101:581-586.
51. Alonso-Llamazares A., Martinez-Cocera C., Dominquez-Ortega J., et al. Nasal provocation test (NPT) with aspirin: a sensitive and safe method to diagnose aspirin-induced asthma (AIA). Allergy 2002, 57:632-635.
52. Nizankowska-Mogilnicka E., Bochenek G., Mastalerz L., et al. EAACI/GALEN guideline: aspirin provocation tests for diagnosis of aspirin hypersensitivity. Allergy 2007, 62:1111-1118.
53. Nizankowska E., Szczeklik A. Glucocorticosteroids attenuate aspirin-precipitated adverse reactions in aspirin intolerant patients with asthma. Ann Allergy 1989, 63:159-164.
54. Stevenson D.D. Aspirin sensitivity and desensitization for asthma and sinusitis. Curr Allergy Asthma Rep 2009, 9:155-163.
55. White A., Bigby T.A., Stevenson D.D. Intranasal ketorolac challenge for the diagnosis of aspirin exacerbated respiratory disease. Ann Allergy Asthma Immunol 2006, 97:190-195.
56. Celik G., Bavbek S., Misirligil A., et al. Release of cysteinyl leukotrienes with aspirin stimulation and the effect of prostaglandin E2 in this release from peripheral blood leukocytes in aspirin-induced asthmatic patients. Clin Exp Allergy 2001, 31:1615-1622.
57. Gamboa P., Sanz M.L., Caballero M.R., et al. The flow-cytometric determination of basophil activation induced by aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) is useful for in vitro diagnosis of the NSAID hypersensitivity syndrome. Clin Exp Allergy 2004, 34:1448-1457.
58. Kowalski M.L., Ptasińska A., Jedrzejczak M., et al. Aspirin-triggered 15-HETE generation in peripheral blood leukocytes is a specific and sensitive Aspirin-Sensitive Patients Identification Test (ASPITest). Allergy 2005, 60:1139-1145.
59. Ebo D.G., Leysen J., Mayorga C., et al. The in vitro diagnosis of drug allergy: status and perspectives. Allergy 2001, 66:1275-1286.